Skip to content
10-Q

Quarterly Report

CNBX PHARMACEUTICALS INC. CNBX

0001683168-26-002899

← back to feed
Filed
Apr 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Apr 14, 2026 1.23B sh
Shares Diluted Q2 2026 · Feb 28, 2026 931.02M sh
Shares Diluted Q2 2026 · Feb 28, 2026 831.39M sh
Shares Diluted Q2 2026 · Feb 28, 2025 32.1M sh
Shares Diluted Q2 2026 · Feb 28, 2025 31.76M sh
Operating Cash Flow Q2 2026 · Feb 28, 2026 −$77.96K
Operating Cash Flow Q2 2026 · Feb 28, 2025 −$90.74K
Short Term Debt Q2 2026 · Feb 28, 2026 $75K
Short Term Debt Q2 2026 · Aug 31, 2025 $0
Cash And Equivalents Q2 2026 · Feb 28, 2026 $12.15K
Cash And Equivalents Q2 2026 · Aug 31, 2025 $15.11K
Stockholders Equity Q2 2026 · Feb 28, 2026 −$2.53M
Stockholders Equity Q2 2026 · Nov 30, 2025 −$2.57M
Stockholders Equity Q2 2026 · Aug 31, 2025 −$2.5M
Stockholders Equity Q2 2026 · Feb 28, 2025 −$2.57M
Stockholders Equity Q2 2026 · Oct 31, 2024 −$2.51M
Stockholders Equity Q2 2026 · Aug 31, 2024 −$2.48M
Current Liabilities Q2 2026 · Feb 28, 2026 $2.55M
Current Liabilities Q2 2026 · Aug 31, 2025 $2.51M
Current Assets Q2 2026 · Feb 28, 2026 $14.9K
Current Assets Q2 2026 · Aug 31, 2025 $18.44K
Total Assets Q2 2026 · Feb 28, 2026 $14.9K
Total Assets Q2 2026 · Aug 31, 2025 $18.44K
Eps Diluted Q2 2026 · Feb 28, 2026 $0.00
Eps Diluted Q2 2026 · Feb 28, 2026 $0.00
Eps Diluted Q2 2026 · Feb 28, 2025 $0.00
Eps Diluted Q2 2026 · Feb 28, 2025 $0.00
Eps Basic Q2 2026 · Feb 28, 2026 $0.00
Eps Basic Q2 2026 · Feb 28, 2026 $0.00
Eps Basic Q2 2026 · Feb 28, 2025 $0.00
Eps Basic Q2 2026 · Feb 28, 2025 $0.00
Sga Expense Q2 2026 · Feb 28, 2026 $72.96K
Sga Expense Q2 2026 · Feb 28, 2026 $136.97K
Sga Expense Q2 2026 · Feb 28, 2025 $64.74K
Sga Expense Q2 2026 · Feb 28, 2025 $101.58K
Rd Expense Q2 2026 · Feb 28, 2026 $0
Rd Expense Q2 2026 · Feb 28, 2026 $0
Rd Expense Q2 2026 · Feb 28, 2025 $0
Rd Expense Q2 2026 · Feb 28, 2025 $0
Net Income Q2 2026 · Feb 28, 2026 −$44.1K
Net Income Q2 2026 · Feb 28, 2026 −$157.82K
Net Income Q2 2026 · Feb 28, 2025 −$69.79K
Net Income Q2 2026 · Feb 28, 2025 −$69.79K
Net Income Q2 2026 · Feb 28, 2025 −$104.14K
Operating Income Q2 2026 · Feb 28, 2026 −$72.96K
Operating Income Q2 2026 · Feb 28, 2026 −$136.97K
Operating Income Q2 2026 · Feb 28, 2025 −$64.74K
Operating Income Q2 2026 · Feb 28, 2025 −$101.58K
Gross Profit Q2 2026 · Feb 28, 2026 $0
Gross Profit Q2 2026 · Feb 28, 2026 $0
Gross Profit Q2 2026 · Feb 28, 2025 $0
Gross Profit Q2 2026 · Feb 28, 2025 $0
Cost Of Revenue Q2 2026 · Feb 28, 2026 $0
Cost Of Revenue Q2 2026 · Feb 28, 2026 $0
Cost Of Revenue Q2 2026 · Feb 28, 2025 $0
Cost Of Revenue Q2 2026 · Feb 28, 2025 $0
Revenue Q2 2026 · Feb 28, 2026 $0
Revenue Q2 2026 · Feb 28, 2026 $0
Revenue Q2 2026 · Feb 28, 2025 $0
Revenue Q2 2026 · Feb 28, 2025 $0